BA12 - Hormone therapy, estrogen metabolism and risk of breast cancer or hip fracture in the WHI hormone trial

Related Papers

Hormone therapy, estrogen metabolism and risk of hip fracture in the WHI HT Trial

Approved Proposal, Cauley, Jane et al., 2008/12 MSID: 917
Keywords: Hip Fracture; Estrogen Metabolites; Estrogen Metabolism; 16a-Hydroxy Estrone; 2-Hydroxy Estrone; Hormone Therapy
Related Studies: BA12

Endogenous sex hormones, estrogen metabolism, hormone therapy, and risk of breast cancer in the WHI HT Trial

Approved Proposal, Mackey, Rachel et al., 2012/4 MSID: 1742
Keywords: Breast Cancer; Endogenous Sex Hormones; Estrogen Metabolites; Estrogen Metabolism; 16a-Hydroxy Estrone; 2-Hydroxy Estrone; Hormone Therapy
Related Studies: BA12, W10

Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women’s Health Initiative Hormone Therapy Trial

Rachel Mackey et al., 2012/8 PubMed #22933427 MSID: 916
In the Women's Health Initiative Hormone Trials (WHI-HT), breast cancer risk was increased with estrogen plus progestin (E+P) but not with unopposed estrogen (E-alone). We hypothesized that E+P would preferentially metabolize to 16a-hydroxyestrone (16a-OHE1) rather than 2-hydroxyestrone (2-OHE1), and that breast cancer risk would be associated with baseline and 1 year changes in estrogen metabolites: positively for 16a-OHE1 levels and negatively for levels of 2-OHE-1 and the 2:16 ratio.In a pros...
Keywords: Breast Cancer; Estrogen Metabolites; Estrogen Metabolism; 16a-Hydroxy Estrone; 2-Hydroxy Estrone; Hormone Therapy
Related Studies: BA12

All Ancillary Studies

Page Navigation
THE WOMEN’S HEALTH INITIATIVE
THE WOMEN’S HEALTH INITIATIVE

The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services.

© 2021 Women’s Health Initiative. All rights reserved